Skip to main content
. 2020 Apr 7;108(3):596–605. doi: 10.1002/cpt.1817

Figure 2.

Figure 2

Cancer types and gene alterations in NGS testing. (a) Number of enrolled patients by cancer type (n = 528). (b) Overall alterations in the 364 patients in NGS testing. Mutations, amplifications, fusions, and deletions are distinguished by color. (c) Genes classified according to potential clinical “actionability” by level of evidence. CNS, central nervous system; NGS, next‐generation sequencing; PNS, peripheral nervous system.